| Ol (lots) | Call Price | Strike Price | Put Price | Ol (lots) |
|---|---|---|---|---|
| - | - | 4,000 | ₹5.8 -10.07% | 1,6258.33% |
| - | - | 4,200 | ₹11.85 0% | 4,7500% |
| - | - | 4,300 | - | - |
| - | - | 4,350 | ₹14.6 0% | 1,8750% |
| - | - | 4,400 | ₹22 4.76% | 2,000166.66% |
| - | - | 4,450 | ₹22.8 14% | 1,6258.33% |
| - | - | 4,500 | ₹37.3 47.43% | 17,6258.46% |
| 3750% | ₹304.85 0% | 4,550 | ₹30 0% | 1250% |
| 1250% | ₹341.3 0% | 4,600 | ₹64 65.58% | 6,50036.84% |
| 1250% | ₹249.85 0% | 4,650 | ₹82.45 74.68% | 2,00077.77% |
| 1,12550% | ₹171.5 -25.61% | 4,700 | ₹100 57.85% | 21,1259.74% |
| 625150% | ₹172.45 -13.88% | 4,750 | ₹84.8 0% | 1,2500% |
| 6,250108.33% | ₹112 -34.34% | 4,800 | ₹150 52.12% | 32,3757.91% |
| 6,00041.17% | ₹100 -29.87% | 4,850 | ₹173 46.61% | 6,625-5.35% |
| 13,6250% | ₹75.55 -36.27% | 4,900 | ₹176.55 22.26% | 20,125-5.84% |
| 3,3750% | ₹101.5 1.24% | 4,950 | ₹179.75 0% | 2,8750% |
| 24,375-8.01% | ₹50 -38.3% | 5,000 | ₹280 37.69% | 20,7509.93% |
| 4,125-15.38% | ₹45 -33.28% | 5,050 | ₹215.45 0% | 1,5000% |
| 31,7506.27% | ₹34.5 -32.28% | 5,100 | ₹281.45 0% | 16,2500% |
| 1,5000% | ₹40.1 0% | 5,150 | ₹345.85 0% | 1250% |
| 15,1258.03% | ₹22.55 -31.66% | 5,200 | ₹393.4 0% | 3,1250% |
| 62525% | ₹19.7 -24.8% | 5,250 | ₹377.6 0% | 1250% |
| 6,3756.25% | ₹16 -11.84% | 5,300 | ₹485 0% | 8750% |
| 3,6250% | ₹19 0% | 5,350 | - | - |
| 8,7500% | ₹13.8 0% | 5,400 | - | - |
| 1,1250% | ₹12 0% | 5,450 | - | - |
| 17,875-3.37% | ₹6.5 -42.47% | 5,500 | - | - |
| 1250% | ₹38.1 0% | 5,550 | - | - |
| 8,1250% | ₹4.5 0% | 5,600 | ₹555 0% | 1250% |
| 5,8750% | ₹3 0% | 5,700 | - | - |
This inspection, conducted from March 10 through March 13, 2025, was to evaluate compliance with the legal standards concerning bioequivalence studies.
The company saw its revenues increase by 1.5% YoY at ₹3,374 crore from ₹3,324 crore.
The serum contains liposomal azelaic acid, liposomal 4-butyl resorcinol, tranexamic acid, alpha arbutin, and niacinamide.
R&D expenses rose to ₹146.5 crore, making up 4.3% of total revenue, compared to ₹115.8 crore (3.4% of revenue) in the previous year.
This comes after competing private equity firms TPG Capital, Apax Partners, and KKR withdrew their original interest.
Alkem will conduct clinical trials of 'SON-080' in India, with Sonnet's support for global and local regulatory submissions.
According to sources, the floor price would be ₹5,616 per share, which is 3% lower than the current market price (CMP).
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
